Oxford Vacmedix UK - novel immunotherapy

Effective immunotherapy for all patient types

With our unique recombinant overlapping peptide (ROP) platform we aim to make safe, highly efficacious immunotherapies that are HLA unrestricted, applicable to a wide range of cancers and available to as many patients as possible.

Recombinant Overlapping Peptides (ROP)

Novel technology invented by Professor Shisong Jiang

Find Out More

Investor Information

Seeking investment for Phase 2 clinical trials (OVM-200) and Phase 1 clinical trials (OVM-100)

Find Out More

Pipeline - a rich mix of clinical & development assets

Future developments and research being explored incl mRNA delivery

Find Out More

Redefining personalised medicine

Our vision for cancer therapeutics

University of Oxford technology

Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemo and radiotherapy. The Oxford Vacmedix ROP technology has a unique dual mode of action which significantly enhances the immunogenicity of the vaccines and is applicable for all HLA types. This completely new proprietary approach to immunotherapy redefines the definition of personalised medicine. ROP vaccines promise effective treatment of cancer, making it easier to deliver and much more economical than existing personalised medicine.

Novel technology significantly enhances the immunogenicity of peptide vaccines.

"Personalised medicine redefined"

Safety and immunogenicity of TSA with the simplicity of TAA

Applicable to Multiple Tumour Types

Survivin (SVN) is a tumour-associated antigen highly expressed in c90% of cancers

Tests & PatientsnServed In 2022

Free Patient VisitsnDone Each Month

Specialized Centers nIn 24 States

Client SatisfactionnRate For Services

No Serious Adverse Events (SAEs)

Strong Immune Response

Dual Mode of Action

Completed UK Phase 1 clinical trial shows strong preliminary data

Our lead immunotherapy, OVM-200, has completed Phase 1 clinical trials in the UK to treat patients with non small cell lung cancer, ovarian cancer and prostate cancer. Results show an excellent safety profile, a very strong dual mode of action immune response, both for antibodies and T cells, and some early indications of clinical efficacy.

Our Edge - Recombinant Overlapping Peptides (ROPs):

Excellent safety profile

Strong immune response

Dual mode of action

Our vision for cancer therapeutics:- with our unique ROP platform we aim to make safe, highly efficacious immunotherapies that are HLA unrestricted, applicable to many cancers, and available to as many patients as possible

No Serious Adverse Events (SAEs)

Strong Immune Response

Dual Mode of Action

Ongoing UK Phase 1 clinical trial with strong preliminary data

Whilst peptide vaccines are a potentially safe, immunogenic cancer treatment option, low efficacy has hindered shared antigen peptide vaccines in clinical trials. Others failed to progress despite good data due to drug complexity.

Our Edge - Recombinant Overlapping Peptides (ROPs):

1000_F_1290336709_tJyPcsv3fmUUPImzL6T9tX2CK6ixOhyL

Excellent safety profile

Strong humoral response

Strong cell-mediated response

Our vision for cancer therapeutics:- with our unique ROP platform we aim to make safe, highly efficacious immunotherapies that are HLA unrestricted, applicable to various cancers, are accessible off-the-shelf and available to as many patients as possible.

Novel Technology

1000_F_53644926_0mvUCIxCCTvIa7BAIFuUa3xsaNA9lbeb

The Science of Recombinant Overlapping Peptides (ROPs)

Oxford Vacmedix has created a universal, off-the-shelf vaccine that targets the immune system to tumor cells in over 90 percent of cancers.
In this video, we demonstrate how the ROP-Survivin Vaccine teaches the immune system to fight cancer.

Find Out More

Stay up-to-date with our progress

News & Articles

University of Oxford Spinout

A spinout from the University of Oxford, Oxford Vacmedix UK (OVM) is a clinical-stage biopharma developing advanced therapeutic cancer vaccines.

University of Oxford Spinout

A spinout from the University of Oxford, Oxford Vacmedix UK (OVM) is a clinical-stage biopharma developing advanced therapeutic cancer vaccines.

Helping To Deliver Answers For Health Questions!

Fixed Commitment To Excellence And Quality Of Our Test Results.

The insights we gain through testing then fuel our drug development practice, by identifying patterns and even individuals who might benefit from enrollment in specific drug trials. nnWith the support of our diagnostics capabilities to deliver drug trials that are both reliable.

Values and Culture